01—Abstract
Summary
Summary of the 8-K filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported financial results for the first quarter of 2026 (quarter ended April 3, 2026, presented as March 31, 2026) in a press release furnished as Exhibit 99.1 to this Form 8-K filed May 5, 2026.
Total revenues were $610.8 milliona, compared with $555.4 million in the prior-year period, driven by net product revenues of $555.0 million (versus $513.3 million), which the company attributed primarily to higher sales volume. Collaboration revenues were $55.8 million, versus $42.2 million. GAAP net income was $210.5 million, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, a year earlier.
Non-GAAP net income was $232.8 millionb, or $0.87 per diluted share. Exelixis maintained its fiscal 2026 guidance, which does not reflect any revenue from a potential U.S. approval and launch of zanzalintinib in previously treated metastatic colorectal cancer. The key regulatory item is the FDA's acceptance of the New Drug Application for zanzalintinib in combination with atezolizumab, under standard review with a PDUFA target action date of December 3, 2026.
Pipeline updates include expected topline STELLAR-304 results in the second half of 2026, an expected mid-2026 final analysis of overall survival in patients without liver metastases in STELLAR-303, expected initiation of STELLAR-316 in mid-2026, and the start of Merck's LITESPARK-034 phase 3 trial in April 2026. On capital allocation, Exelixis had repurchased $590.6 millionc of stock under its October 2025 program at an average price of $43.14 per share as of quarter end, and expected to complete the remaining amount in May 2026. The Board authorized an additional repurchase of up to $750 million of common stock by December 31, 2027.
02—Key points
Key Highlights
- Total revenues of $610.8 million versus $555.4 million in the prior-year period; net product revenues of $555.0 million, with the increase attributed primarily to higher sales volume.
- GAAP net income of $210.5 million ($0.79 diluted EPS) versus $159.6 million ($0.55 diluted EPS); non-GAAP diluted EPS of $0.87 versus $0.62.
- FDA accepted the zanzalintinib NDA (with atezolizumab) for previously treated metastatic colorectal cancer under standard review, with a PDUFA target action date of December 3, 2026.
- Fiscal 2026 guidance maintained: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion, excluding any potential zanzalintinib CRC launch revenue.
- Newly authorized stock repurchase of up to $750 million by December 31, 2027, following the October 2025 program, which had $590.6 million repurchased as of quarter end and was expected to be completed in May 2026.
- Pipeline milestones expected in 2026 include STELLAR-304 topline results in the second half, STELLAR-316 initiation in mid-2026, and STELLAR-202 and a STELLAR-002 expansion cohort in the second half.
- Research and development expenses declined to $199.9 million from $212.2 million, mainly due to lower clinical trial and manufacturing costs.
03—Questions
Frequently Asked Questions
What drove the revenue increase in the first quarter of 2026?
Net product revenues rose to $555.0 million from $513.3 million, primarily due to higher sales volume. Collaboration revenues increased to $55.8 million from $42.2 million, mainly due to higher royalties on cabozantinib sales outside the U.S. generated by partner Ipsen and higher milestone-related revenues, partially offset by lower development cost reimbursements.
Is zanzalintinib under regulatory review, and when is the decision expected?
Yes. The FDA accepted the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer under standard review, with a PDUFA target action date of December 3, 2026. The company's 2026 guidance does not reflect any revenue from a potential approval and launch.
How much stock has Exelixis been repurchasing, and what is the new authorization?
Under the October 2025 program, Exelixis had repurchased $590.6 million of stock at an average price of $43.14 per share as of quarter end and expected to complete the $750 million program in May 2026. The Board also authorized up to an additional $750 million of repurchases by December 31, 2027. The company is not obligated to repurchase any amount and may modify or discontinue the programs at any time.
What are the key upcoming clinical data readouts?
Exelixis expects topline results from the phase 3 STELLAR-304 trial (zanzalintinib with nivolumab versus sunitinib in previously untreated non-clear cell renal cell carcinoma) in the second half of 2026, depending on event rates. The final analysis of overall survival in patients without liver metastases in the STELLAR-303 trial is expected in mid-2026, depending on event rates.
What drove the difference between GAAP and non-GAAP earnings?
Non-GAAP net income excludes stock-based compensation, adjusted for the related income tax effect. In the first quarter of 2026, stock-based compensation was $12.3 million in research and development and $16.7 million in selling, general and administrative expenses, with a $6.8 million income tax effect, producing non-GAAP net income of $232.8 million versus GAAP net income of $210.5 million.
04—Continue